SweetNight Proudly Introduces the All-New CoolNest(TM) Memory Foam Mattress
Wilmington, Delaware--(Newsfile Corp. - May 20, 2025) - SweetNight, a trailblazer in sleep innovation, introduced the CoolNest™ Memory Foam Mattress, its most advanced cooling sleep solution to date. Engineered specifically for individuals who experience overheating or night sweats, the mattress is designed to improve sleep quality by maintaining a consistently cooler and more comfortable sleeping environment, which has quickly become the new favorite of most hot sleepers and night sweaters.
This mattress is tailor-made for hot sleepers, night sweaters, back pain sufferers, and anyone who believes a better day starts with deeper rest. With temperature regulation so effective it's been described as "cool enough for a polar bear," the mattress delivers measurable comfort benefits for those seeking better sleep and better mornings.
Cannot view this video? Visit:https://www.youtube.com/watch?v=BR6FMRHzm5U
Designed with SweetNight's proprietary CoolNest™ Cooling System, the mattress delivers up to 8° cooler sleep temperatures, offering a much-needed escape from night sweats and sleep disruptions.
The magic begins with the CoolNest™ Cover, engineered with 3D weaving technology and over 10,000 micro-ventilation pores to boost breathability by 35%. The PCMflux™ High Resilience Foam in the middle features a hollow core structure that is three times more breathable than standard foams and is infused with an advanced phase change material (PCM) that stabilizes body temperature during the night.Enjoy a cool and cozy night's sleep
But the CoolNest™ Memory Foam Mattress isn't just cool, it's also designed with an ergonomic 5-zone support for excellent support. Certified by the American Chiropractic Association (ACA), the mattress is meticulously designed to maintain spinal alignment, relieve pressure points, and improve overall sleep posture. By addressing common causes of poor sleep such as misalignment and tension, CoolNest™ enables users to recover more effectively overnight, improve mobility, and start each day with greater energy, focus, and resilience. Whether you're a side sleeper, back sleeper, or someone who changes positions frequently, the mattress adapts intelligently to your body-transforming rest into a tool for better living.
As an honorary member of the International Sleep Products Association (ISPA), SweetNight is committed to health and sustainability, ensuring a safe and comfortable sleep environment for every user. Its fabrics are OEKO-TEX certified and its foam is CertiPUR-US certified.
"Sleep is no longer a luxury-it's a necessity," says a SweetNight spokesperson. "CoolNest™ was born from our commitment to helping people sleep deeper, cooler, and better.
About SweetNight
SweetNight is a rapidly growing global mattress and sleep solutions company bringing high quality sleep related products to the world.
Starting from humble beginnings as an affordable mattress manufacturer, SweetNight realised that "modern sleepers needed modern sleep solutions", and began developing high-quality mattresses using eco-friendly production techniques. The initial SweetNight product line, which focused on affordable luxury was a great success in the American market, with endorsement from industry experts and media such as Forbes, SleepFoundation, Slumber Yard and more.
The CoolNest™ Memory Foam Mattress is now available for purchase on SweetNight.com as well as on their Amazon, Wayfair and Walmart stores.
Cooler Nights, Better Mornings Start Now.
Discover more at: www.sweetnight.com
Contact:Jenelyn Mainarsupport@sweetnight.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252572
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT™ platform and proven Flow Electroporation® technology, widely recognized for its efficient and scalable transfection capabilities, utilized in over 19 active clinical and commercial programs, with Ori's innovative next-generation cell therapy manufacturing platform, IRO® (ee-RO). The collaboration will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes. As a key component of this joint effort, Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation. MaxCyte's technology offers unparalleled flexibility and efficiency in transfecting cells at clinical scale, seamlessly integrating with diverse upstream and downstream processes within cell therapy workflows. The IRO platform complements this by introducing automated fluid handling, customizable mixing, and the OriConnect® tubeless sterile connection system, enhancing cell culture efficiency and scalability. Together, these complementary technologies provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently. Maher Masoud, President and CEO of MaxCyte, commented, 'We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes. This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients.''Our partnership with MaxCyte is another example of Ori's dedication to providing flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing,' said Jason C. Foster, CEO of Ori Biotech. 'By integrating modular, best-of-breed technologies, we're raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale.' Through their shared commitment to innovation and industry collaboration, MaxCyte and Ori Biotech are enabling developers of advanced therapies to adopt integrated, best-of-breed solutions, accelerating the path from research to commercialization and making next-generation treatments more accessible to patients globally. About MaxCyte At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at and follow us on X and LinkedIn. About Ori Biotech Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori's next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products' clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics. For news and updates, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits, outcomes, and impact of the collaboration between MaxCyte and Ori Biotech; the potential for improving clinical success and commercial viability through new manufacturing standards; and the intention to accelerate development timelines, increase access to next-generation cell therapies, and deliver transformative treatments to patients globally. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which MaxCyte operates, as well as management's current beliefs and assumptions. Words such as 'aims,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'should,' 'continue,' and variations of such words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict and are often beyond the control of the companies involved. Actual outcomes and results may differ materially from those expressed or implied in these forward-looking statements due to various factors, including changes in market conditions, technological advancements, regulatory developments, and the success of ongoing research and evaluation efforts. Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended May 8, 2025. These documents are available through the Investor Menu, Financials section, under 'SEC Filings' on the Investors page of our website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, MaxCyte does not undertake any obligation to update or revise any forward-looking statements to reflect new information, events, or circumstances after the date of this release. MaxCyte Contacts: US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@ Oak Street CommunicationsKristen Whitekristen@ Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500 UK IR AdviserICR HealthcareMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@ Ori Biotech Contact: Debby Betzmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 hours ago
- Yahoo
NanoHive Medical Sublicenses DirectSync's Piezoelectric Patents to Explore Development of Hive™ Soft Titanium® 3D Printed Spine Interbody Fusion "Smart Implant"
BOSTON, June 10, 2025 /PRNewswire/ -- NanoHive Medical, LLC, a leading innovative 3D printed spinal implant technology company is pleased to announce that the company has secured the exclusive sublicense of DirectSync Surgical's piezoelectric implantable sensor technology for the field of spinal fusion. DirectSync Surgical had licensed the technology from the University of Kansas. NanoHive is exploring the advancement of successful proof-of-concept research to potentially develop bone stimulating and remote monitoring/data collection sensor technology housed in the company's highly innovative spinal interbody fusion device lattice which is currently commercialized in the company's Hive™ Soft Titanium® portfolio of 3D printed spinal interbody fusion devices. In October 2023, the company reported the initiation of a research collaboration with DirectSync Surgical. Based on the preliminary research generated, the company ascertained that their proprietary rhombic dodecahedron lattice technology was uniquely capable of transferring significant energy from the encapsulated piezoelectric sensor. The company is currently in the process of working with the US Food and Drug Administration (FDA) on the transfer of the Breakthrough Device Designation from DirectSync to NanoHive. Patrick O'Donnell, President & CEO of NanoHive stated, "NanoHive's Soft Titanium® technology is the ideal interbody fusion implant to deliver a sensor with data collection and bone stimulation capability. The company is excited about the prospect of leading the way with the development of a technological leap in the interbody fusion device category. Our view of the future of innovation in spine devices emphasizes that new technologies must demonstrate an improvement to patient virtual care and clinical outcomes as well as connectivity with enabling surgical technologies and artificial intelligence. These advancements must also deliver cost-efficiencies to the various stakeholders involved in the spine patient's episode-of-care. More meaningful and frequent data collection that can ultimately be utilized as a predictive tool will be essential to this vision." About NanoHive Medical LLC NanoHive Medical is a pioneer and leading innovator in 3D printed spinal interbody fusion implants and instrumentation. The company's proprietary, biomimetic Soft Titanium® technology clearly distinguishes their products in the $2.4B U.S. spinal interbody fusion device market. The Hive™ portfolio of interbody fusion devices provide surgeons and their patients ideal biomechanical elastic modulus properties, clear and precise diagnostic imaging capability, osteoblast cell attraction and integration – all features that lead to consistently strong fusion constructs and efficacious clinical experiences. NanoHive Medical is based in Woburn, Massachusetts U.S.A. Contact: Patrick O'Donnell, CEO & President, NanoHive Medical LLC, Website: About DirectSync Surgical DirectSync Surgical is a rising leader in smart patient powered implant devices. With a commitment to innovation and foundational research, the company develops and manufactures advanced tools that empower both spinal and orthopedic professionals to achieve superior surgical outcomes. DirectSync Surgical's products are not available for sale in the US. Contact: Leighton LaPierre, COO, DirectSync Surgical, leighton@ Website: NanoHive Medical, LLC | 12 Gill Street, Suite 4500 | Woburn, MA 01801 | 844-943-5433 View original content to download multimedia: SOURCE NanoHive Medical Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Yahoo
Foresight Diagnostics and Partners to Present Independent Validation Data for its CLARITY™ MRD Assay at the 2025 European Hematology Association (EHA) Congress and International Conference on Malignant Lymphoma (ICML)
- Data will be presented as an oral presentation at EHA on Thursday, June 12, 2025, and at ICML on Thursday, June 19, 2025 BOULDER, Colo., June 10, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading developer of ultra-sensitive minimal residual disease (MRD) detection technologies, today announced that validation data demonstrating the prognostic performance of its CLARITY™ MRD assay in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) will be featured as encore oral presentations at two upcoming international conferences: the 2025 European Hematology Association (EHA) Congress (June 12–15, in Milan, Italy) and the 18th International Conference on Malignant Lymphoma (ICML) (June 17–21, in Lugano, Switzerland). This multi-center study, conducted in collaboration with Amsterdam University Medical Centers, the Hemato-Oncology Foundation for Adults in the Netherlands (HOVON), and the Netherlands Comprehensive Cancer Organization (IKNL), highlights real-world results using Foresight CLARITY™ MRD on patients who were treated with frontline chemotherapy across over 50 centers in the Netherlands and Belgium. "We're grateful to present our data at major medical meetings this spring, validating our science and the real-world utility of ultra-sensitive ctDNA-MRD technology," said David Kurtz, M.D., Ph.D., Chief Medical Officer of Foresight Diagnostics. "These presentations and the recent incorporation of ctDNA-MRD testing in B-cell lymphoma clinical guidelines give us confidence as we prepare to launch in the clinical market in 2026 and integrate Foresight CLARITY into routine clinical practice." Lead study authors Steven Wang, M.D., and Martine Chamuleau, M.D., Ph.D., Amsterdam UMC, added: "Our findings confirm that ultra-sensitive ctDNA-MRD detection provides meaningful prognostic information beyond standard imaging and clinical factors. We believe this assay can support better risk stratification than imaging alone and inform post-treatment management decisions in DLBCL." Oral presentation details for EHA: Title: Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial Presenter: Martine Chamuleau, MD, PhD (Amsterdam UMC) Session: Aggressive Non-Hodgkin lymphoma - Clinical (Observational) Time: Thursday, June 12 | 5:00 p.m. – 5:15 p.m. CEST / 11:00 a.m. – 11:15 a.m. ET Room: Brown Hall 3 Abstract number: S240 Oral presentation details for ICML: Title: Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national HOVON trial Presenter: Martine Chamuleau, MD, PhD (Amsterdam UMC) Session: Session 6: Liquid biopsy for response assessment Time: Thursday, June 19 | 2:15 p.m. – 2:30 p.m. CEST / 8:15 a.m. – 8:30 a.m. ET Room: Polivalente room, East Campus USI Article number: 041 In addition to the oral presentation, Foresight's technology will be highlighted in other presentations, including: Title: Prognostic Value of Circulating Tumor DNA (ctDNA) Detection by PhasED-Seq After Axicabtagene ciloleucel (Axi-cel) Therapy in Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Meeting: EHA 2025 Sponsor: Kite PharmaPresenter: Jeffrey Gregg, MD (Foresight Diagnostics) Session: Poster Session I | Poster HallDate/Time: Friday, June 13 | 6:30 p.m. – 7:30 p.m. CEST / 12:30 p.m. – 1:30 p.m. ET Abstract: #PF1002 Title: The Correlation of Mutational Profiles and Valemetostat Efficacy in Patients With R/R PTCL in the Phase 2 VALENTINE-PTCL01 Trial Meeting: ICML 2025 Sponsor: Daiichi Sankyo Presenter: Pier Luigi Zinzani, MD, PhD (University of Bologna) Session: "Focus On" Session Biology and Therapy of T-cell Lymphomas | Room B Date/Time: Saturday, June 14 | 10:05 a.m. – 10:15 a.m. CEST / 4:05 a.m. – 4:15 a.m. ET Article Number: 164 About Foresight Diagnostics Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. Its liquid biopsy platform, Foresight CLARITY™, is a novel assay that measures minimal residual disease (MRD) with reported detection limits in parts per million. The improved sensitivity of Foresight CLARITY™ has the potential to provide actionable information to physicians and biopharmaceutical companies to enable personalized treatment approaches for patients with solid tumor and hematologic malignancies. For more information, please visit and follow us on X, LinkedIn, and Bluesky. View original content to download multimedia: SOURCE Foresight Diagnostics, Inc.
